Sanofi stops phase 3 trial of riliprubart in CIDP patients
Investing.com Gold reports: Sanofi stops phase 3 trial of riliprubart in CIDP patients. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Sanofi stops phase 3 trial of riliprubart in CIDP patients. Full body text was unavailable at ingest time, so this brief is based on headline context.